Jyong Biotech (MENS) Cash & Equivalents (2024 - 2025)
Jyong Biotech's (MENS) quarterly Cash & Equivalents came in at $250000.0 in Q4 2025, up 147.52% year-on-year from $101000.0 in Q4 2024, and up 89.39% quarter-over-quarter from $132000.0 in Q2 2025.
Jyong Biotech (MENS) Cash & Equivalents (2024 - 2025) Analysis & Trends
Jyong Biotech's Cash & Equivalents history runs 2 years deep, the most recent figure standing at $250000.0 for Q4 2025.
- On a quarterly basis, Cash & Equivalents rose 147.52% year-over-year to $250000.0 in Q4 2025; TTM through Dec 2025 was $250000.0, a 147.52% increase from a year earlier, with the FY2025 full-year figure at $250000.0, up 147.52% from the prior year.
- Cash & Equivalents climbed to $250000.0 in Q4 2025 per MENS's latest filing, from $132000.0 in the prior quarter.
- Across five years, Cash & Equivalents topped out at $250000.0 in Q4 2025 and bottomed at $101000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Jyong Biotech | 181.07 Mn | 181.07 Mn | - | 250,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 250,000.00 |
| Jun 30, 2025 | 132,000.00 |
| Dec 31, 2024 | 101,000.00 |